Ark Therapeutics Group plc

Ark Therapeutics Group plc

Ark Therapeutics is loading its boat with therapies that target cancer and vascular disease. The biotech company has one product on the market in the UK and the US -- Kerraboot, a wound dressing that treats chronic leg and foot ulcers. Lead candidate Cerepro has shown promise in extending the lives of brain tumor patients. And it has two other clinical-stage candidates that may treat cancer-related muscle wasting and prevent blood vessels from blocking after vascular graft surgery. The firm develops and markets its own products in key markets, such as Europe and the US; it largely develops drugs for indications where it has a good chance of getting the regulatory privileges of Fast Track or Orphan Drug status.

Contact Details

Office Address

Ark Therapeutics Group plc
79 New Cavendish Street, London, UK W1W6XB
Phone: +44-20-7388-7722
Fax: +44-20-7388-7805

Executives

CEO

Nigel Parker

CFO and Company Secretary

Martyn D. Williams

Business Reviews for Ark Therapeutics Group plc

Related Companies